Compositions and methods for the therapy and diagnosis of lung cancer
AssigneeCorixa Corporation
InventorsPaul A. Algate, Michael J. Lodes, Tongtong Wang, Liqun Fan, Patricia D. McNeill
Life of this patent
Estimating the term…
Abstract
Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.
Claims17
An isolated polynucleotide comprising a sequence selected from the group consisting of:
- (a) sequences provided in SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723, 732, 736, 737, 740, 741, 744 and 746;
- (b) complements of the sequences provided in SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723, 732, 736, 737, 740, 741, 744 and 746;
- (c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723, 732, 736, 737, 740, 741, 744 and 746;
- (d) sequences that hybridize to a sequence provided in SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723, 732, 736, 737, 740, 741, 744 and 746, under moderately stringent conditions;
- (e) sequences having at least 75% identity to a sequence of SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723, 732, 736, 737, 740, 741, 744 and 746;
- (f) sequences having at least 90% identity to a sequence of SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723, 732, 736, 737, 740, 741, 744 and 746;
- and
- (g) degenerate variants of a sequence provided in SEQ ID NOs:588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723, 732, 736, 737, 740, 741, 744 and 746.
An oligonucleotide that hybridizes to a sequence recited in SEQ ID NOs:
- 588, 598, 603, 611, 616, 622, 625, 629, 636, 639, 641, 649-651, 655, 656, 659, 660, 664, 665, 675, 681, 686, 703, 720, 723, 732, 736, 737, 740, 741, 744 and 746 under moderately stringent conditions.
Dependencies are inferred from the claim text.